Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 3/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25577709 | 0.95 | ALOX5 (0.39) | ALOX5PRKDCLIMK1PIK3CDBRD4 | |
| SCHEMBL25577316 | 0.95 | ALOX5 (0.39) | ALOX5PRKDCLIMK1PIK3CDBRD4 | |
| SCHEMBL25577448 | 0.94 | ALOX5 (0.40) | ALOX5PRKDCLIMK1PIK3CDBRD4 | |
| SCHEMBL25577638 | 0.94 | ALOX5 (0.39) | ALOX5PRKDCLIMK1 | |
| SCHEMBL25577352 | 0.92 | ALOX5 (0.35) | ALOX5PRKDCLIMK1PIK3CDBRD4 | |
| SCHEMBL25577702 | 0.91 | PRKDC (0.41) | ALOX5PRKDCPIK3CDBRD4PIK3CA | |
| SCHEMBL23867302 | 0.91 | ALOX5 (0.39) | ALOX5PRKDCLIMK1PIK3CDBRD4 | |
| SCHEMBL25577680 | 0.90 | ALOX5 (0.39) | ALOX5PRKDCLIMK1 | |
| SCHEMBL23867303 | 0.90 | ALOX5 (0.38) | ALOX5PRKDCPIK3CDBRD4PIK3CA | |
| SCHEMBL25577630 | 0.90 | PRKDC (0.41) | ALOX5PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230180597-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | ESR1, L1CAM, ESR2 | ALOX5 1615/4885PRKDC 4878/4885LIMK1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.